На этой странице перечислены больницы направления «Трансплантация печени и гепатобилиарная хирургия» (включая Face Transplant Surgery) в Хайдарабад, Индия, включая KIMS Hospitals, Secunderabad, Yashoda Hospitals, Secunderabad, Apollo Hospital DRDO, Apollo Hospitals, Jubilee Hills.
Спросите нас о «Face Transplant Surgery» в Хайдарабад, Индия
Оставьте свои данные — наша команда координации свяжется с вами и расскажет о следующих шагах.
Сравните 4 аккредитованных больниц (Трансплантация печени и гепатобилиарная хирургия) в Хайдарабад, Индия
Рекомендуем🇮🇳 KIMS Hospitals, Secunderabad
Больница занимает 1-е место в этом списке по указанному рейтингу (4.8/5, 743 отзывов).
🇮🇳 Yashoda Hospitals, Secunderabad
Больница занимает 2-е место в этом списке по указанному рейтингу (4.7/5, 518 отзывов).
🇮🇳 Apollo Hospital DRDO
Больница занимает 3-е место в этом списке по указанному рейтингу (4.5/5, 82 отзывов).
🇮🇳 Apollo Hospitals, Jubilee Hills
Больница занимает 4-е место в этом списке по указанному рейтингу (4.1/5, 44 отзывов).
Как мы выбираем эти больницы
Больница появляется на этой странице, если направление «Трансплантация печени и гепатобилиарная хирургия» указано среди её специализаций и она находится в Хайдарабад, Индия. Сортировка — по указанному рейтингу (по убыванию), без редакционного рейтинга «лучших».
Как выбрать лучшую больницу для «face transplant surgery» в Хайдарабад, Индия?
Выбор подходящей больницы для «face transplant surgery» — важное решение в вашем пути лечения. Вот на что стоит обратить внимание:
Международная аккредитация
Ищите больницу с международной аккредитацией, например JCI или NABH — см. отметки аккредитации у каждой больницы ниже.
Специализация
Убедитесь, что в больнице есть отделение, специализирующееся на «Трансплантация печени и гепатобилиарная хирургия», а не только общая помощь.
Мощность и опыт
Количество коек и год основания, указанные ниже, отражают масштаб и операционный опыт больницы.
Прозрачность стоимости
Запросите детализированную смету перед поездкой — используйте наш калькулятор стоимости для первичной оценки.
Что нужно знать о процедуре «Face Transplant Surgery»
Face transplant surgery, or facial allotransplantation, is one of the most complex composite tissue transplant procedures in reconstructive surgery, involving the transfer of a donor's facial structures — including skin, muscle, nerves, and vasculature — to a recipient with severe facial disfigurement. Global success rates at high-volume centers now approach 85–90% for graft survival at one year, with continued improvements in immunosuppression protocols and microsurgical technique. GAF Healthcare connects international patients with India's and the UAE's leading craniofacial and transplant surgery teams, offering world-class outcomes at a fraction of the cost compared to North America or Western Europe. Hospital Stay: 21–35 days (ICU + step-down ward) • Total Stay in Country (Fit-to-Fly): 12–16 weeks (minimum 3 months post-operative stability required before international travel) • Success Rate: 85–90% graft survival at 1 year (leading centers)
Clinical Overview
Facial allotransplantation is a vascularized composite allotransplantation (VCA) — a category distinct from solid organ transplants in that it simultaneously transfers multiple tissue types (skin, subcutaneous fat, muscle, bone, cartilage, mucosa, and peripheral nerves) as a single, perfused anatomical unit. The indication arises from severe, unreconstructable facial disfigurement secondary to high-voltage electrical burns, ballistic injuries, oncologic resection, severe chemical burns, or congenital conditions such as neurofibromatosis type 1 with massive plexiform involvement. The physiological consequence of such disfigurement extends beyond cosmesis: patients suffer profound functional deficits including inability to eat, speak, breathe spontaneously, or close the eyelids, compounded by severe psychological morbidity including major depressive disorder and social withdrawal. The procedure is performed under general anesthesia over 16–30 hours by an interdisciplinary team comprising craniofacial surgeons, plastic and reconstructive surgeons, microsurgeons, transplant immunologists, neurologists, and anesthesiologists. The donor face is procured from a brain-dead, ABO-compatible cadaveric donor under the same ethical and legal framework as solid organ donation. Recipient preparation involves detailed 3D CT angiography and MRI mapping of the facial vasculature, motor and sensory nerve mapping using electromyography (EMG) and nerve conduction studies (NCS), and virtual surgical planning (VSP) using photogrammetric facial modeling. The standard of care requires a multidisciplinary transplant board review, formal psychiatric clearance, and ethics committee approval prior to listing. Post-operatively, recipients require lifelong immunosuppression — typically a triple-drug regimen comprising a calcineurin inhibitor (tacrolimus, targeting trough levels of 8–12 ng/mL in the first year), an antiproliferative agent (mycophenolate mofetil), and low-dose corticosteroids — along with induction therapy using antithymocyte globulin (ATG) or basiliximab at the time of transplant. Sensory reinnervation (the return of light touch and temperature discrimination) typically begins at 3–6 months post-transplant; motor reinnervation and voluntary facial movement recovery follows a 9–24 month trajectory, contingent on nerve coaptation technique and recipient age.
Who is a Candidate?
• ELIGIBLE CANDIDATES: • Patients aged 18–60 years with severe, unreconstructable facial disfigurement affecting >25% of the facial surface area • Disfigurement secondary to: high-voltage electrical burns, ballistic/blast injuries (gunshot wounds), severe thermal or chemical burns, failed or maximal conventional reconstructive surgery, or massive plexiform neurofibromatosis • Functional deficits in two or more of the following domains: oral incompetence (inability to eat/speak), nasal airway obstruction, corneal exposure due to eyelid loss, or significant midfacial skeletal destruction • Formal psychological evaluation confirming adequate coping capacity, realistic expectations regarding motor recovery timeline, and absence of active psychosis or untreated major psychiatric disorder • Demonstrated ability to comply with lifelong immunosuppression and follow-up protocols (critical — non-compliance is the leading cause of late rejection) • ABO blood group compatibility with donor pool; HLA sensitization workup (Panel Reactive Antibody, PRA) — patients with PRA >80% require desensitization protocols • REQUIRED PRE-OPERATIVE DIAGNOSTICS: • 3D CT Angiography of facial and cervical vasculature (mapping of external carotid artery branches) • MRI Face and Neck with gadolinium contrast (soft tissue and nerve mapping) • Electromyography (EMG) and Nerve Conduction Studies (NCS) of residual facial musculature • Virtual Surgical Planning (VSP) with photogrammetric 3D facial surface scanning • Full HLA typing and crossmatch; Panel Reactive Antibody (PRA) screening • Comprehensive metabolic panel, CBC, coagulation screen (PT/INR, aPTT) • Infectious disease screening: HIV, HBV, HCV, CMV, EBV, tuberculosis (IGRA/Quantiferon-TB Gold) • Echocardiography (ECHO) and pulmonary function tests (PFT) for anesthetic risk stratification • Ophthalmologic evaluation if periorbital involvement • Formal psychiatric evaluation and neuropsychological testing • Bone densitometry (DEXA scan) as baseline prior to corticosteroid immunosuppression • ABSOLUTE CONTRAINDICATIONS: • Active malignancy or history of malignancy within 5 years (due to immunosuppression-related tumor promotion risk) • Active systemic infection or uncontrolled sepsis • Severe cardiovascular disease (EF <35%, recent MI within 6 months) • Severe hepatic or renal insufficiency (eGFR <30 mL/min/1.73m²) that would preclude calcineurin inhibitor use • Active substance dependence (alcohol, opioids) without sustained remission • Active, untreated psychosis or personality disorders incompatible with treatment adherence • Pregnancy • RELATIVE CONTRAINDICATIONS: • Diabetes mellitus with end-organ damage (increases infection and wound healing risk under immunosuppression) • Obesity (BMI >35): significantly increases perioperative complications • Prior sensitization with PRA >80% without available desensitization protocol
Treatment Options & Approaches
SURGICAL APPROACHES IN FACIAL ALLOTRANSPLANTATION: 1. PARTIAL FACE TRANSPLANT (Zone-Specific Allotransplantation): Indicates transfer of a specific anatomical subunit — most commonly the central face (nose, lips, chin, and associated musculature) or the lower face (mandibular zone). This approach is used when disfigurement is zone-limited and adjacent recipient tissue can serve as a vascular inflow zone. Vascular anastomoses are performed to the facial artery and vein under operative microscope (magnification ×10–25). Nerve coaptation targets the infraorbital branch (V2) of the trigeminal nerve for sensory restoration and the buccal and marginal mandibular branches of the facial nerve (CN VII) for motor restoration. Operative time: 16–22 hours. 2. FULL FACE TRANSPLANT (Total Facial Allotransplantation): The most extensive VCA procedure, encompassing transfer of the entire facial soft tissue envelope including eyelids, nose, lips, cheeks, chin, forehead skin, and potentially underlying skeletal components (maxilla, mandible, zygoma). Bilateral vascular anastomoses are performed to the external carotid arteries and external jugular or facial veins. Motor coaptation involves the main trunk or pes anserinus of the facial nerve bilaterally. Sensory coaptation targets all three trigeminal divisions (V1, V2, V3). Operative time: 22–30+ hours. This approach has been performed in over 50 documented cases globally, including landmark cases at Brigham and Women's Hospital (Boston), Henri Mondor Hospital (Paris), and the Cleveland Clinic. 3. OSTEOMYOCUTANEOUS COMPOSITE FACE TRANSPLANT: Includes transfer of skeletal components (typically the mid-face Le Fort III segment, maxilla, or mandibular symphysis) in addition to soft tissue. Indicated when recipient skeletal destruction precludes adequate soft tissue support. Rigid fixation is achieved with titanium plates and screws following digital pre-operative osteotomy planning via VSP software (e.g., Materialise ProPlan CMF). This variant requires additional surgical time for skeletal fixation but yields superior long-term functional and aesthetic outcomes for patients with blast or ballistic injuries. 4. IMMUNOSUPPRESSION PROTOCOLS (CRITICAL TECHNICAL DETAIL): • Induction: Antithymocyte globulin (ATG, rabbit-derived, 1.5 mg/kg/day × 5 days) or Basiliximab (IL-2 receptor antagonist, 20 mg IV on Days 0 and 4) • Maintenance Triple Therapy: Tacrolimus (FK506) + Mycophenolate Mofetil (MMF, 1–1.5 g twice daily) + Prednisolone (tapered to 5–10 mg/day by 6 months) • Rejection Surveillance: Protocol skin biopsies at 1, 3, 6, 12 months using the Banff 2007 VCA classification system (Grade I–IV acute rejection) • Emerging Protocols: Some centers are investigating minimization or withdrawal of steroids using mTOR inhibitors (sirolimus/everolimus) and co-stimulation blockade (belatacept) to reduce long-term nephrotoxicity from calcineurin inhibitors • Opportunistic Infection Prophylaxis: Trimethoprim-sulfamethoxazole (PCP), valganciclovir (CMV prophylaxis for CMV-mismatched pairs), antifungal prophylaxis (fluconazole) 5. ADVANCED TECHNOLOGIES USED: • Virtual Surgical Planning (VSP) and 3D-printed surgical cutting guides • Intraoperative indocyanine green (ICG) fluorescence angiography for real-time perfusion assessment of the transplanted tissue • Nerve monitoring with intraoperative EMG • Hypothermic machine perfusion (HMP) for extended preservation of the donor face graft (up to 6–8 hours cold ischemia time is acceptable; machine perfusion extends this window) • Robotic-assisted microsurgery is under investigation at select centers for suture placement in anastomosis under tremor-filtered magnification
Восстановление
PHASE 1 — PRE-OPERATIVE EVALUATION & LISTING (3–6 months before transplant): • Comprehensive multidisciplinary evaluation: craniofacial surgery, transplant medicine, psychiatry, ophthalmology, speech therapy • Completion of all diagnostic workup (3D CT angio, MRI, HLA typing, PRA, EMG/NCS, ECHO, PFTs, DEXA) • Virtual surgical planning session: 3D photogrammetric facial scanning, VSP software modeling of recipient anatomy • Formal listing on the national transplant registry; ABO/HLA compatibility data submitted • Psychological counseling and informed consent process (typically multiple sessions covering realistic motor recovery expectations, immunosuppression burden, and rejection risk) • Dental rehabilitation and oral hygiene optimization (infection risk reduction under immunosuppression) PHASE 2 — DONOR MATCHING & PROCUREMENT (Variable — hours to months on waitlist): • Notification of ABO-compatible brain-dead donor; urgent crossmatch and final HLA compatibility confirmation • Simultaneous donor procurement and recipient preparation in adjacent operating rooms • Cold ischemia time minimized; target under 4 hours (acceptable up to 6 hours with standard cold storage; HMP extends window) • Recipient facial tissue resection performed first (skin and underlying tissue degloving) to prepare recipient vascular pedicles and nerve stumps PHASE 3 — TRANSPLANT SURGERY (Day 0, 16–30 hours): • General anesthesia, arterial line, central venous access, urinary catheter • Recipient preparation: elevation of facial flap, identification and tagging of facial artery/vein bilaterally, exposure of facial nerve branches • Allograft inset: skeletal fixation first (if osteomyocutaneous), then vascular anastomoses under operative microscope (artery first, then vein) • Reperfusion: graft becomes pink/warm; ICG fluorescence angiography confirms perfusion • Nerve coaptation: CN VII (motor) and trigeminal branches (sensory) using 9-0 or 10-0 nylon epineural sutures or fibrin glue-assisted coaptation • Skin closure; wound drains placed • Induction immunosuppression administered intraoperatively PHASE 4 — ICU & ACUTE POST-OPERATIVE PERIOD (Days 0–14): • ICU monitoring: hourly clinical Doppler assessment of graft perfusion (color, turgor, capillary refill, temperature probe on graft) • Implantable Doppler probe on venous anastomosis for continuous perfusion signal monitoring • Strict head-of-bed elevation at 30° to reduce edema • NPO initially; nasogastric feeding tube for nutrition • Tacrolimus trough levels checked daily; target 10–15 ng/mL in first 2 weeks • Daily wound care; swelling peaks at Days 3–5, begins to resolve by Day 10 • Protocol skin punch biopsy at Day 7–10 (Banff grading) • Speech therapy assessment begins (oral motor function evaluation) PHASE 5 — STEP-DOWN WARD (Days 14–35): • Transfer from ICU when graft perfusion is stable and patient is hemodynamically independent • Immunosuppression fine-tuning; transition to oral tacrolimus, MMF, and prednisolone • Initiation of structured facial rehabilitation: mirror-guided facial movement exercises, neuromuscular re-education • Nutritional rehabilitation: transition from NG feeds to soft oral diet as oral competence allows • Psychology and social work support sessions • Discharge planning: patient and caregiver education on wound care, medication administration, rejection warning signs PHASE 6 — OUTPATIENT RECOVERY IN INDIA/UAE (Weeks 5–16 before fit-to-fly): • Weekly outpatient visits: clinical examination, Doppler assessment, blood draws (tacrolimus trough, CBC, renal function, LFTs, CMV PCR) • Protocol skin biopsy at 3 months • Occupational therapy and facial physiotherapy: 45–60 minutes daily • RECOVERY MILESTONES: • Weeks 4–6: Swelling substantially resolved; early light touch sensation in zone of sensory coaptation • Months 3–4: Protective sensation (pain/temperature) established; voluntary lip movement may begin • Months 6–12: Progressive voluntary facial movement (smile, brow raise); cosmetic appearance stabilizes • Months 12–24: Maximum motor reinnervation achieved; speech intelligibility normalized • Fit-to-fly clearance requires: stable tacrolimus levels for ≥4 weeks, no active rejection episode in prior 8 weeks, adequate patient/caregiver competency in medication management, confirmed follow-up arrangement with transplant team in home country PHASE 7 — LONG-TERM FOLLOW-UP (Lifelong): • Annual protocol biopsies; periodic imaging • Lifelong immunosuppression monitoring: renal function, bone density (DEXA annually), skin cancer surveillance (annual dermatology), metabolic monitoring (HbA1c, lipids) • Long-term risks managed: chronic rejection (intimal thickening of graft vessels), calcineurin inhibitor nephrotoxicity, post-transplant lymphoproliferative disorder (PTLD), opportunistic infections
Возможные риски
Facial allotransplantation carries a distinct and serious risk profile that every candidate must understand before proceeding. The most critical early risk is vascular thrombosis of the anastomosed artery or vein, which can occur in the first 72 hours and constitutes a surgical emergency requiring immediate return to the operating room for anastomotic revision; failure to salvage the graft within 4–6 hours of ischemia results in complete graft loss. Acute cellular rejection — classified by the Banff 2007 VCA grading system — occurs in approximately 85% of recipients at some point in the first year (most episodes are Grade I–II and respond to high-dose corticosteroid pulses or ATG); however, Grade III–IV rejection with dermis and vascular involvement requires aggressive rescue immunosuppression and carries graft loss risk. Chronic rejection, manifested as progressive graft vasculopathy (intimal hyperplasia of facial vessels) and fibrosis, is the leading cause of late graft loss beyond 5 years and currently has no established treatment beyond optimizing maintenance immunosuppression. The long-term immunosuppression burden introduces a separate category of systemic risks: calcineurin inhibitor nephrotoxicity leading to chronic kidney disease (reported in 30–40% of VCA recipients by 5 years, with some progressing to renal replacement therapy); metabolic complications including new-onset diabetes after transplant (NODAT), hypertension, and dyslipidemia; significantly elevated risk of skin malignancies (squamous cell carcinoma and basal cell carcinoma) and post-transplant lymphoproliferative disorder (PTLD), driven by EBV reactivation under immunosuppression. Opportunistic infections — cytomegalovirus (CMV), pneumocystis jirovecii pneumonia (PCP), fungal infections — are significant risks especially in the first year. Graft failure requiring surgical removal has been documented in international case series and leaves patients with severe secondary disfigurement, often worse than pre-transplant baseline. Patients must also be counseled on the psychological dimension: while most recipients report significant improvement in quality of life, some experience identity integration difficulties, post-traumatic stress related to the procedure, or depression secondary to the chronic disease burden of immunosuppression. Mortality risk associated with the procedure itself is estimated at 1–3% at experienced centers, primarily from anesthetic complications, sepsis, or thrombotic events in the perioperative period.
Почему GAF Healthcare
GAF Healthcare provides comprehensive end-to-end non-medical coordination for international patients traveling to India or the UAE for facial allotransplantation. INDIA LOGISTICS: • e-Medical Visa Assistance: GAF Healthcare prepares and submits the complete e-Medical Visa application package on the patient's behalf, including the formal invitation letter from the treating hospital (required by the Indian government for medical visa approval). e-Medical Visas permit stays of up to 60 days (extendable) and allow entry for one primary attendant on a co-applicant e-Medical attendant visa. • Hospital Coordination: We liaise directly with the craniofacial and transplant departments at NABH- and JCI-accredited partner hospitals in Delhi (AIIMS, Fortis Vasant Kunj, Medanta The Medicity), Mumbai (Kokilaben Dhirubhai Ambani Hospital), and Chennai (Apollo Hospitals) to schedule the pre-operative evaluation visit. • Airport-to-Hospital Transfers: Private ambulance or accessible vehicle transfer from Indira Gandhi International (DEL), Chhatrapati Shivaji Maharaj (BOM), or Chennai International (MAA) airports, coordinated with flight arrival details. • Accommodation: Long-stay serviced apartments within 1–2 km of the treating hospital for the patient's attendant(s), typically at $40–$80/night (India). We negotiate monthly rates for the extended 12–16 week stay. • Translation & Language Support: Dedicated patient coordinators fluent in Arabic, Russian, Swahili, French, and other languages are assigned as a single point of contact throughout the journey. • Telemedicine Pre-Consultation: Before travel, a formal video consultation with the treating surgeon and transplant immunologist is arranged to review all existing records, imaging, and blood work — avoiding unnecessary early travel. UAE LOGISTICS: • Visa Entry: Most nationalities receive visa-on-arrival or 30-day entry permits for the UAE. For nationalities requiring a prior visa, GAF Healthcare coordinates with Dubai Health Authority (DHA)- and DOH (Abu Dhabi)-licensed hospitals to issue the required medical treatment NOC supporting the patient's visa application. • Partner Hospitals: Cleveland Clinic Abu Dhabi (JCI- and DHA-accredited), Mediclinic City Hospital Dubai, and American Hospital Dubai are among GAF Healthcare's accredited UAE partners with composite tissue transplant capabilities. • Airport Transfers: Private vehicle or medical-grade transport from Dubai International (DXB) or Abu Dhabi International (AUH) airports. • Accommodation: Coordinated hotel or serviced apartment bookings near the treating facility at competitive rates; attendant accommodation packages available. • Insurance & Financial Facilitation: GAF Healthcare assists with pre-authorization documentation for international health insurance claims and provides itemized pro-forma cost estimates for insurance submission. • Post-Discharge Follow-Up Coordination: Upon the patient's return home, GAF Healthcare provides a complete medical discharge summary, immunosuppression protocol documentation, and facilitates introduction to a local transplant physician or immunologist for ongoing monitoring.
Частые вопросы о процедуре «Face Transplant Surgery»
What is the cost of Face Transplant Surgery (Facial Allotransplantation) in India vs. the UAE?
How long do I need to stay in the country before I am fit to fly home after a face transplant?
What is the success rate of face transplant surgery, and what does 'success' mean for this procedure?
Как GAF Healthcare помогает выбрать лучшую больницу для «face transplant surgery» в Хайдарабад, Индия
Найдите лучшие больницы для «face transplant surgery» в Хайдарабад, Индия
На этой странице представлено 4 больниц в Хайдарабад, Индия, чтобы вы могли сравнить аккредитацию и специализации в одном месте.
Поддержка, когда она нужна
Отправьте нам свои медицинские отчёты в WhatsApp или по email — наша медицинская команда изучит их и предложит больницу и план лечения.
Прозрачные, всё включено цены
Мы предоставляем единую детализированную смету, покрывающую расходы больницы и проживание — без скрытых платежей.
Организация визы, поездки и проживания
После выбора больницы мы помогаем оформить визовое приглашение, забронировать проживание рядом с больницей и организовать трансфер.
Хотите узнать примерную стоимость лечения? Используйте наш калькулятор стоимости для персональной оценки.
Частые вопросы о «Face Transplant Surgery» в Хайдарабад, Индия
Сколько больниц направления «Трансплантация печени и гепатобилиарная хирургия» представлено в Хайдарабад, Индия?
Как вы выбираете больницы для списка?
Сколько стоит лечение в Хайдарабад, Индия?
Следующий шаг
Отправьте нам свои медицинские отчёты — наша команда предложит больницу и план лечения для «Face Transplant Surgery» в Хайдарабад, Индия.
Свяжитесь с нами, если заметите неточность на этой странице.